Multicenter trial of the therapeutic effect of a newly developed antiplatelet agent, satigrel, on biopsy-proven chronic rejection after kidney transplantation

Transplant Proc. 1997 Feb-Mar;29(1-2):266-71. doi: 10.1016/s0041-1345(96)00633-1.

Authors

S Teraoka¹, K Ota, K Tanabe, K Takahashi, H Toma, T Yasumura, N Yoshimura, T Oka, S Takahara, A Okuyama, T Haba, K Uchida, S Sugiyama, S Ohshima, T Sato, H Okazaki, K Morozumi

Affiliation

¹ Kidney Center, Tokyo Women's Medical College, Japan.

PMID: 9122990
DOI: 10.1016/s0041-1345(96)00633-1

No abstract available

Publication types

Clinical Trial
Multicenter Study

MeSH terms

6-Ketoprostaglandin F1 alpha / blood
Adult
Biopsy, Needle
Blood Urea Nitrogen
Creatinine / metabolism
Fatty Acids, Monounsaturated / therapeutic use*
Female
Graft Rejection / blood
Graft Rejection / drug therapy*
Humans
Kidney Transplantation / immunology
Kidney Transplantation / physiology*
Male
Platelet Aggregation Inhibitors / therapeutic use*
Thromboxane B2 / blood
Time Factors

Substances

Fatty Acids, Monounsaturated
Platelet Aggregation Inhibitors
Thromboxane B2
6-Ketoprostaglandin F1 alpha
Creatinine
Satigrel